Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Clinical, News,

Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET)…

Read more

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

Events, News,

Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September…

Read more

NCCN Guidelines Updated to Include PSMA-PET Imaging

Clinical, News,

Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68…

Read more

FDA Approves Phase II Kidney Cancer Therapy Study

Clinical, News,

Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy,…

Read more

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

ASX, News,

Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product…

Read more

Telix In-Licences Novel Tumour Microenvironment PET Tracer

ASX, News,

Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de…

Read more

Japanese Prostate Cancer Imaging Study Completes Enrolment

Clinical, News,

Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa…

Read more

Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

ASX, News,

Telix announces collaboration with Kettering Health on PSMA-targeting…

Read more

Michael Didocha Joins Telix as Chief Financial Officer, Americas

ASX, News,

Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas…

Read more

Samantha McSherry Joins Telix as Director of Commercial Operations ANZ

ASX, News,

Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New…

Read more
1 … 28 29 30 31 32 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings